Local intrapulmonary recombinant human activated protein C after bronchial lipopolysaccharide challenge in healthy volunteers

Open-label trial of drotrecogin alfa in No single canonical disease name; "pulmonary inflammation" is a descriptive term, not a specific disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Neutrophil responses in bronchoalveolar lavage fluid, Alveolar macrophage responses and 3 more. Planned start Aug 2008; status: not yet recruiting.